KalVista Pharmaceuticals, Inc. (KALV) Financials
KALV Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| 2024-01-31 | 114.0 million | 25.4 million |
| 2023-10-31 | 138.7 million | 24.3 million |
| 2023-07-31 | 160.3 million | 21.0 million |
| 2023-04-30 | 183.2 million | 22.2 million |
KALV Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| 2024-01-31 | -27.6 million | 2.7 million |
| 2023-10-31 | -20.0 million | 3.2 million |
| 2023-07-31 | -26.7 million | 3.3 million |
| 2023-04-30 | -22.7 million | 2.4 million |
KALV Net Income
No data available :(
KALV Cash and Debt
Graph available only for supporters. Become a supporter to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| 2024-01-31 | 75.6 million | - | 7.4 million |
| 2023-10-31 | 103.2 million | - | 7.7 million |
| 2023-07-31 | 123.3 million | - | 8.0 million |
| 2023-04-30 | 149.4 million | - | 8.2 million |
KALV Shares Outstanding
KALV Expenses
Graph available only for supporters. Become a supporter to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| 2024-01-31 | 19000 | 22.5 million | 10.6 million | 207000 |
| 2023-10-31 | 205000 | 19.1 million | 10.7 million | - |
| 2023-07-31 | 6000 | 19.3 million | 9.8 million | - |
| 2023-04-30 | 69000 | 24.0 million | 7.8 million | - |
KALV Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| 2024-01-31 | - | 207000 |
| 2023-10-31 | - | 197000 |
| 2023-07-31 | - | 199000 |
| 2023-04-30 | - | 324000 |
KALV
Price: $10.78
52 week price:
Earnings Per Share: -3.12 USD
P/E Ratio: -5.02
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 731100
Ebitda: -22.6 millionMarket Capitalization: 498.2 million